Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans
Source: Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans: Cell Reports
Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans
Source: Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans: Cell Reports
Dietary Plant Lectins Appear to Be Transported from the Gut to Gain Access to and Alter Dopaminergic Neurons of Caenorhabditis elegans, a Potential Etiology of Parkinson’s Disease
ognitive benefit of acute WGOE supplementation does not persist with chronic treatment
Seems that cognitive benefit of green oat supplementation does not persist over time
Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease – Full Text View.
For Indians, it appears that it would be most prudent to have a diet with about 50 per cent carbohydrate (using complex carbs and whole grains such as brown rice or whole wheat) about 20-25 per cent protein (preferably from vegetable proteins such as legumes and pulses) and the remaining 25-30 per cent from healthy fats like monounsaturated fats (e.g. groundnut oil or mustard oil and nuts and seeds) along with plenty of green leafy vegetables. Such a diet may not immediately give dramatic results as far as weight reduction is concerned. However, it will be sustainable in the long term and will be less risky and certainly more healthy and also help prevent non-communicable diseases such as diabetes, cardiovascular disease and certain cancers.
Scientists recently tested probiotics in a roundworm model of Parkinson’s. A particular bacterium had a protective effect and improved symptoms.
Managing Rheumatoid Arthritis with Dietary Interventions
Source: Managing Rheumatoid Arthritis with Dietary Interventions – PMC
Researchers have found that excess levels of calcium in brain cells may lead to the formation of toxic clusters that are the hallmark of Parkinson’s disease.
Source: Calcium may play a role in the development of Parkinson’s disease
The most pressing need in Parkinson’s disease (PD) clinical practice is to identify agents that might slow down, stop or reverse the neurodegenerative process of Parkinson’s disease and therefore avoid the onset of the most disabling, dopa-refractory symptoms of the disease. These include dementia, …
Although many toxins and neurological insults that damage the basal ganglia and/or the substantia nigra result in neurological disorders which include parkinsonian features (see below), one toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), appears to target relatively specifically those neurons that are involved in Parkinson’s disease. MPTP has been used to develop animal models for testing new therapies in the human disease. Investigations of the mechanisms of MPTP toxicity have also provided insights regarding the possible pathogenesis of Parkinson’s disease.
View all available recorded events
Source: Event recordings
Parkinson’s disease (PD) patients using dopamine agonists can develop withdrawal symptoms, referred to as dopamine agonist withdrawal syndrome (DAWS), under dose tapering or discontinuation of these drugs. DAWS includes a severe stereotypical cluster of psychiatric and psychological symptoms encompa …
Source: Rasagiline Withdrawal Syndrome in Parkinson’s Disease – PubMed